DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Orphan Drugs was estimated at US$179.5 ...

The One Big Beautiful Bill Act removed a number of orphan drugs from being subject to price negotiations, and this could cost the Medicare program $8.8 billion over the course of about 10 years. That ...

The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend an Inflation Reduction Act (IRA) provision currently affecting treatments ...

The 20th and 21st centuries have witnessed a profound revolution in medical science, significantly enhancing living standards and extending the life expectancy of billions worldwide. However, certain ...

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges. In this episode, Kristi Martin, a longtime Washington, DC–based policy ...

IFx-2.0 received orphan drug designation for cutaneous melanoma, offering benefits like market exclusivity and tax credits. Phase 1 study data showed IFx-2.0 benefits patients resistant to anti-PD1 ...

Rilzabrutinib is an investigational, oral reversible Bruton tyrosine kinase inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to rilzabrutinib for the treatment of ...